[Guidelines for RA therapies].
Ochi
Takahiro
T
Sagamihara National Hospital.
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000534:rehabilitation / Q000628:therapy*; D019643:Arthroplasty, Replacement; D004359:Drug Therapy, Combination; D006801:Humans; D000069285:Infliximab; D007555:Isoxazoles / Q000009:adverse effects / Q000627:therapeutic use; D007564:Japan; D000077339:Leflunomide; D008727:Methotrexate / Q000009:adverse effects / Q000627:therapeutic use; D019637:Orthopedic Procedures; D017410:Practice Guidelines as Topic; D011239:Prednisolone / Q000009:adverse effects / Q000627:therapeutic use
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D007555:Isoxazoles; D011239:Prednisolone; D000069285:Infliximab; D000077339:Leflunomide; D008727:Methotrexate